Buyer’s diligence counsel see your company differently than do you.
You see a balance sheet. They see twenty distinct risk vectors, each priced into the bid spread before the indication of interest is even submitted. The difference between a buyer who comes in at the top of their range and a buyer who comes in at the bottom is, in many transactions, a function of what the buyer’s diligence team finds and how they price it.
This is Part 3 of the Pre-Sale Playbook series. Part 1 covered the 18 months before the banker. Part 2 covered the strategic alternatives review itself. This issue is about cleaning the balance sheet in the months between signing the banker’s engagement letter and signing the merger agreement.
1. The litigation matrix.
Every open litigation matter your company carries into a sale process gets priced by the buyer’s diligence team using a simple matrix:
Probability of liability × Plausible damages × Risk premium for uncertainty = Buyer’s discount
The “risk premium for uncertainty” is the killer. Even matters with low probability of liability and modest damages get priced punitively because the buyer has incomplete information.
The corrective practice — covered in Part 1 — is to triage each matter and resolve where possible. But for matters that must be carried into the deal, the goal is to compress the uncertainty component. That means:
— Comprehensive matter summaries (one to two pages each) updated within 30 days of the diligence opening.
— Counsel’s current best estimate of probable outcomes and ranges.
— A clear narrative for why each matter is reserved at the level it is reserved.
— Insurance coverage analysis with carrier confirmations.
When the buyer’s diligence team can read your matter summaries and reach roughly the same conclusion your reserve analysis reached, the risk premium compresses. When they have to do their own analysis from raw filings, the risk premium expands.
2. The contracts assignment audit.
Most commercial agreements in a pharma or biotech portfolio contain change-of-control or assignment provisions. Most go unexamined until the deal is in motion. By then, it is too late to renegotiate.
The contracts that matter most for assignment review:
— Material supply and manufacturing agreements (typically the highest-risk; CMOs sometimes have termination rights on change of control).
— License agreements — both in-licenses and out-licenses. In-license assignment requirements are often strict, especially with academic licensors and government partners.
— Distribution and commercialization agreements. Geographic partners may have territory-defense or change-of-control termination rights.
— Material customer contracts (GPO agreements, hospital system contracts).
— IT and data agreements — sometimes overlooked but often containing change-of-control consent requirements.
The corrective practice: in the months before the diligence room opens, conduct an assignment-provisions audit of all material contracts. Categorize each into (a) assignable without consent, (b) assignable with notice, (c) assignable with consent and a likelihood of obtaining it, and (d) not assignable. For matters in category (c), begin the consent process early — counterparty consent timelines in pharma typically run 60–120 days.
When the assignment-provisions audit is completed during the pre-diligence period, you can initiate those consents before the public deal is announced. This allows each counterparty to respond in normal commercial course rather than under the implicit pressure of an announced transaction.
3. The IP cleanup.
The buyer’s IP diligence team will examine three things: ownership, encumbrance, and chain of title.
Ownership questions: Are all material patents and applications assigned to the company on the face of the record (PTO assignment records — not just internal records)? For collaborative-developed IP, is joint-inventorship resolved and recorded? For inventions developed under sponsored research, is the funding source’s IP rights cleanly documented?
Encumbrance questions: Are there licenses granted to third parties that survive a sale? What are their scope and exclusivity? Are there security interests recorded against the IP? Are there march-in rights, government use rights, or Bayh-Dole obligations?
Chain-of-title questions — the hardest: Has every former employee who contributed to a material patent signed an effective assignment? (Termination agreements are not assignment agreements.) For patents acquired through prior transactions, are all upstream assignments recorded? For patents licensed from academic institutions, are the institutional assignments to the university (from the inventor) on record?
The corrective practice: run a clean-room IP audit 6–12 months before the anticipated diligence opening. Most pharma companies discover at least three gaps in chain of title that take 30–90 days to remediate.
4. The regulatory file.
The buyer’s regulatory diligence team will request, at minimum:
— Every Establishment Inspection Report (EIR) and Form 483 from the last five years for every facility manufacturing material product.
— Every FDA correspondence file for every approved product and every product in active development.
— Every Untitled Letter, Warning Letter, or other enforcement-related correspondence.
— Every adverse-event report disclosure beyond the regulatory minimum.
— Pharmacovigilance system master files.
The corrective practice — one I have implemented in every late-stage company I have advised — is to maintain a “regulatory readiness binder,” updated quarterly, that contains organized copies of all of the above. When the diligence opens, the buyer’s team gets the binder in week one.
A practitioner’s tip: if your company has had any Form 483 observations in the last 24 months, prepare a one-page summary for each, including the company’s response and the remediation status. The buyer is going to ask. The question is whether you control the narrative or whether they construct it from raw documents.
5. The employment and severance overhang.
Change-of-control severance, change-of-control vesting acceleration, and retention agreements are part of the deal economics. Many sellers underestimate how much.
The buyer will model the total change-of-control payments — severance, accelerated vesting, retention bonuses, parachute tax gross-ups — and either deduct them from the offer price or require the seller to fund them out of seller-side reserves.
The corrective practice: in the months before the banker engagement, produce a complete change-of-control payment schedule. For every employee with a change-of-control entitlement, what triggers it, what is the dollar amount, what is the timing. Then make strategic decisions:
— Which retention agreements should be put in place pre-announcement to stabilize the team through the transaction?
— Which severance arrangements should be renegotiated?
— Are there 280G considerations that require shareholder approval?
These decisions get easier the earlier they are made. Once the deal is signed, every conversation with an executive about their severance becomes a leak risk.
What to do this week
For the GC of a company anticipating a sale process in the next 12–24 months, three concrete actions for this week:
— Pull the assignment-provisions audit. If it does not exist, start it.
— Request the most recent change-of-control payment schedule from HR. If it does not exist, draft the template.
— Schedule a one-hour meeting with the IP team to walk through chain-of-title gaps on the top ten material patents.
None of these are the kind of work that wins recognition in the moment. All of them determine, in aggregate, the difference between a deal that closes at the top of the bid range and a deal that closes at the bottom.
This concludes the Pre-Sale Playbook three-part series.
For the GC, CFO, or CEO of a company facing a sale window without a leader who has been through this before, LaRocca Advisory Services provides fractional CLO engagements specifically for the 12–24 month pre-sale period. Reply to this email or visit GCPlaybook.com.
— John
Know a GC, CLO, or finance leader who’d find this useful? Forward it — genuinely, that’s how The GC Playbook grows.
And if your team has a raise, sale, or audit on the horizon, I take on a few diligence & compliance readiness reviews a year. Just reply to this email.
John (john@laroccaadvisory.com)


